QuantiFERON-TB IGRA Test for TB Screening at Dr. Essa Lab

QuantiFERON-TB IGRA at Dr. Essa Lab

The QuantiFERON-TB IGRA (Interferon-Gamma Release Assay) is a highly advanced, modern blood test used to detect infection by Mycobacterium tuberculosis, the pathogenic bacterium responsible for tuberculosis (TB). Unlike traditional screening methods, this laboratory investigation measures the cell-mediated immune response of the patient to specific tuberculosis antigens. When a person is infected with TB, their T-lymphocytes become sensitized to the bacteria and produce a specific cytokine called interferon-gamma (IFN-γ) when they encounter these antigens again. By measuring the concentration of this cytokine in a controlled laboratory setting, the QuantiFERON-TB IGRA provides a highly accurate assessment of whether the patient has been infected with the tuberculosis bacteria.

At Dr. Essa Lab, Pakistan’s premier diagnostic and laboratory network founded in Karachi, this test is performed using state-of-the-art enzyme-linked immunosorbent assay (ELISA) technology. The assay evaluates the immune response to specific synthetic peptides that simulate mycobacterial proteins: ESAT-6 and CFP-10. These proteins are highly specific to Mycobacterium tuberculosis and are entirely absent from the Bacille Calmette-Guérin (BCG) vaccine strain, as well as from most non-tuberculous mycobacteria. This clinical specificity is of paramount importance in Pakistan, where BCG vaccination is widespread. Traditional skin tests often yield false-positive results in BCG-vaccinated individuals, whereas the QuantiFERON-TB IGRA at Dr. Essa Lab provides a reliable, specific, and objective diagnostic outcome unaffected by prior vaccination.

The clinical value of this test lies in its ability to identify both latent tuberculosis infection (LTBI) and active tuberculosis disease. While the test cannot clinically differentiate between latent and active states on its own, it serves as an invaluable screening tool. Detecting latent TB is crucial because individuals with latent infections carry the bacteria in an inactive state, showing no symptoms and remaining non-infectious. However, they face a lifelong risk of the infection reactivating into active, infectious pulmonary or extrapulmonary tuberculosis, particularly if their immune system becomes compromised. Identifying and treating latent TB is a cornerstone of global public health strategies to eradicate tuberculosis, making the QuantiFERON-TB IGRA an essential diagnostic asset for clinicians across Pakistan.

Clinical Procedure: What to Expect

Patient Preparation

To ensure the utmost accuracy of the QuantiFERON-TB IGRA at Dr. Essa Lab, patients should observe the following preparation guidelines:

• No Fasting Required: Unlike many routine blood chemistry panels, the QuantiFERON-TB IGRA does not require overnight fasting. Patients may eat and drink normally prior to the blood draw.
• Medication Disclosure: It is vital to inform the phlebotomist and your referring physician of all medications you are currently taking, particularly immunosuppressive agents, systemic corticosteroids, or biologic therapies (such as TNF-alpha inhibitors), as these can suppress T-lymphocyte function and potentially lead to indeterminate or false-negative results.
• Timing of Other Tests: If you have recently undergone a live-virus vaccination (such as MMR or yellow fever) or a Tuberculin Skin Test (TST), it is recommended to wait at least four to six weeks before undergoing the QuantiFERON-TB IGRA, as these can temporarily alter cell-mediated immune responses.
• Hydration: Staying well-hydrated prior to the blood collection is recommended to facilitate easier venous access and a smoother phlebotomy experience.

During the Procedure

The collection process for the QuantiFERON-TB IGRA is highly specialized and requires meticulous attention to detail by the trained phlebotomy staff at Dr. Essa Lab:

• Venipuncture: A certified phlebotomist will identify a suitable vein, typically in the antecubital fossa of the arm, cleanse the site with an antiseptic solution, and insert a sterile needle to draw blood.
• Specialized Collection Tubes: Unlike standard blood tests collected in a single tube, the QuantiFERON-TB IGRA requires blood to be drawn directly into four specialized, color-coded QuantiFERON tubes. These tubes must be filled in a specific order and to the exact fill line marked on each tube (1.0 mL per tube) to ensure the correct ratio of blood to antigen.
• The Four Tubes Explained: The set includes a Nil Control Tube (Grey), which measures the baseline IFN-γ level in the patient’s blood; a TB1 Antigen Tube (Green), which detects the CD4+ T-cell response; a TB2 Antigen Tube (Yellow), which detects both CD4+ and CD8+ T-cell responses; and a Mitogen Control Tube (Purple), which acts as a positive control to verify the patient’s overall immune competence.
• Mixing and Handling: Immediately after collection, the phlebotomist will gently shake or invert the tubes ten times to ensure the blood is thoroughly mixed with the antigens coated on the inner walls of the tubes. This step is critical for initiating the immune reaction.
• Incubation and Processing: The tubes are transported promptly to the Dr. Essa Lab processing facility, where they must be incubated at 37°C within 16 hours of collection. During this incubation period, sensitized T-lymphocytes in the blood release IFN-γ in response to the TB antigens. Following incubation, the tubes are centrifuged, and the plasma is harvested to measure the concentration of IFN-γ using an ELISA reader.
• Safety and Comfort: The entire phlebotomy procedure takes less than ten minutes. Patients may experience a mild, temporary pinching sensation at the needle insertion site, but the procedure is safe, sterile, and carries minimal risk.

When is a QuantiFERON-TB IGRA Performed?

Screening for Latent Tuberculosis Infection (LTBI)

Physicians frequently request the QuantiFERON-TB IGRA to screen individuals who are at high risk for latent tuberculosis infection. This includes individuals who have recently immigrated from or traveled extensively to regions with a high burden of tuberculosis, as well as those living in crowded or high-risk environments. Because latent TB is asymptomatic, screening is the only method to identify infected individuals before the disease progresses to an active, transmissible state. Detecting LTBI allows clinicians to initiate preventive therapy, significantly reducing the risk of future active disease.

Pre-Immunosuppressive Therapy Evaluation

Before initiating medical treatments that suppress the immune system, patients must undergo screening for latent tuberculosis. Immunosuppressive therapies, such as tumor necrosis factor (TNF) inhibitors, high-dose systemic corticosteroids, chemotherapy, or pre-transplant immunosuppression, can impair the body’s cell-mediated immunity. If a patient with undiagnosed latent TB begins these therapies, the risk of the infection reactivating into life-threatening active pulmonary or disseminated tuberculosis increases exponentially. The QuantiFERON-TB IGRA provides a highly reliable baseline screening to ensure safe treatment planning.

Healthcare Worker and Occupational Screening

Healthcare professionals, laboratory personnel, and individuals working in correctional facilities or long-term care homes face an increased occupational risk of exposure to active tuberculosis. Routine screening using the QuantiFERON-TB IGRA is a standard protocol in occupational health programs to monitor exposure. Because healthcare workers in Pakistan are highly likely to have received the BCG vaccine, the IGRA is the preferred screening method over the Tuberculin Skin Test, as it eliminates false-positive results associated with prior vaccination, ensuring accurate occupational health tracking.

Investigation of Close Contacts of Active TB Cases

When a case of active pulmonary tuberculosis is diagnosed, public health protocols require the immediate identification and screening of close contacts, such as family members, co-workers, and close friends. The QuantiFERON-TB IGRA is performed to determine if transmission has occurred. If a contact tests positive, they are diagnosed with latent TB (provided active disease is ruled out through clinical and radiological evaluation) and are candidates for preventive therapy, thereby halting the chain of transmission within the community.

Differential Diagnosis in Suspected Active TB

In complex clinical scenarios where a patient presents with symptoms suggestive of active tuberculosis—such as chronic cough, unexplained weight loss, night sweats, or persistent fever—but sputum smears or molecular tests are negative or unavailable, the QuantiFERON-TB IGRA serves as a valuable adjunctive diagnostic tool. A positive result confirms that the patient has been infected with Mycobacterium tuberculosis, supporting the clinical suspicion of active disease when combined with characteristic radiographic findings and clinical presentation, especially in cases of extrapulmonary tuberculosis where obtaining tissue samples is challenging.

What Does a QuantiFERON-TB IGRA Detect?

The QuantiFERON-TB IGRA is designed to detect and quantify specific immunological and clinical parameters, including:

• The presence of viable Mycobacterium tuberculosis infection in the host.
• The quantitative concentration of Interferon-Gamma (IFN-γ) in international units per milliliter (IU/mL).
• The specific cell-mediated immune response of CD4+ helper T-lymphocytes to TB-specific antigens (via the TB1 tube).
• The combined immune response of both CD4+ helper and CD8+ cytotoxic T-lymphocytes to TB-specific antigens (via the TB2 tube).
• The baseline level of interferon-gamma in the patient’s blood in the absence of stimulation (via the Nil control tube).
• The functional viability and responsiveness of the patient’s T-lymphocytes to a non-specific stimulant (via the Mitogen control tube).
• Latent tuberculosis infection (LTBI) in asymptomatic, non-infectious individuals.
• Immunological evidence supporting a diagnosis of active pulmonary tuberculosis.
• Immunological evidence supporting a diagnosis of extrapulmonary tuberculosis (such as TB meningitis, pleural TB, or bone TB).
• The absence of cross-reactive immune responses from prior BCG (Bacille Calmette-Guérin) vaccination.
• The absence of cross-reactive immune responses from most common environmental or non-tuberculous mycobacteria (NTM).
• Indeterminate results caused by severe systemic immunosuppression or advanced immunodeficiency (e.g., advanced HIV/AIDS).
• Indeterminate results resulting from pre-analytical errors, such as delayed incubation or improper blood-to-antigen mixing.
• False-negative results in patients who have been recently infected but have not yet developed a detectable cell-mediated immune response (window period).
• The risk of progression from latent infection to active tuberculosis disease in immunocompromised patients.
• The immunological status of close contacts exposed to an infectious index case of tuberculosis.
• Baseline immunological safety prior to starting biologic therapies or disease-modifying antirheumatic drugs (DMARDs).
• Baseline safety status prior to undergoing solid organ or hematopoietic stem cell transplantation.
• Occupational exposure and infection status in high-risk healthcare and laboratory workers.
• Infection status in patients with chronic medical conditions that increase TB susceptibility, such as diabetes mellitus, silicosis, or end-stage renal disease on hemodialysis.

Turnaround Time and Report Access at Dr. Essa Lab

Dr. Essa Lab is committed to providing rapid, accurate, and highly reliable diagnostic reports. Because the QuantiFERON-TB IGRA involves a precise 16-hour incubation period followed by a sophisticated ELISA laboratory process, the turnaround time for results is typically 24 to 48 hours from the time of sample collection. This efficient processing ensures that clinicians can make timely decisions regarding patient care, particularly when preparing for urgent immunosuppressive therapies or managing close contacts of active TB cases.

Patients can easily access their diagnostic reports through Dr. Essa Lab’s secure online portal or via their dedicated mobile application. Once the laboratory specialists verify the results, an automated SMS notification containing a direct link to download the PDF report is sent to the patient’s registered mobile number. Physical copies of the report can also be collected from any of Dr. Essa Lab’s numerous collection centers located across Karachi and other major cities in Pakistan, ensuring maximum convenience and seamless integration into the patient’s healthcare journey.

QuantiFERON-TB IGRA Findings Overview

The following table outlines the typical parameters evaluated during the QuantiFERON-TB IGRA, along with their clinical interpretation:

Parameter Evaluated	Normal / Expected Findings	Possible Abnormal / Positive Findings
Nil Control Tube (Grey)	Low IFN-γ level (≤ 8.0 IU/mL); indicates minimal baseline immune activation.	Elevated IFN-γ level (> 8.0 IU/mL); may indicate analytical error, presence of heterophile antibodies, or systemic inflammation.
TB1 Antigen minus Nil (Green)	Low IFN-γ response (< 0.35 IU/mL); indicates no significant CD4+ T-cell response to TB antigens.	Elevated IFN-γ response (≥ 0.35 IU/mL and ≥ 25% of Nil); indicates CD4+ T-cell sensitization to Mycobacterium tuberculosis.
TB2 Antigen minus Nil (Yellow)	Low IFN-γ response (< 0.35 IU/mL); indicates no significant CD4+ and CD8+ T-cell response.	Elevated IFN-γ response (≥ 0.35 IU/mL and ≥ 25% of Nil); indicates robust CD4+ and CD8+ T-cell sensitization to TB.
Mitogen Control Tube (Purple)	High IFN-γ response (≥ 0.5 IU/mL); confirms that the patient’s T-lymphocytes are functionally capable of responding.	Low IFN-γ response (< 0.5 IU/mL); indicates T-cell dysfunction, severe lymphopenia, or presence of immunosuppressive factors.
Overall Test Interpretation	Negative; no immunological evidence of Mycobacterium tuberculosis infection.	Positive; immunological evidence of Mycobacterium tuberculosis infection (latent or active).
Indeterminate Result	Not applicable; indicates a valid, interpretable test run.	Indeterminate; occurs when the Nil control is too high or the Mitogen control is too low, rendering the test uninterpretable.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Dr. Essa Lab for QuantiFERON-TB IGRA?

• Experienced Healthcare Professionals: Dr. Essa Lab employs highly qualified pathologists, microbiologists, and laboratory technologists who specialize in advanced immunological assays, ensuring the highest standards of diagnostic accuracy.
• Patient-Focused Care: The laboratory is dedicated to providing a compassionate, comfortable, and seamless experience for every patient, from blood collection to report delivery.
• Quality Diagnostic Services: Utilizing state-of-the-art ELISA technology and automated processing systems, Dr. Essa Lab minimizes human error and delivers highly reproducible and precise results.
• Professional Reporting: Reports are structured clearly, providing detailed quantitative values for all four tubes along with a definitive clinical interpretation to assist referring physicians.
• Modern Diagnostic Approach: Dr. Essa Lab continuously updates its laboratory protocols and equipment to align with global diagnostic standards and evidence-based medical guidelines.
• Comfortable Environment: All collection centers are designed to be clean, hygienic, and welcoming, ensuring a stress-free environment for patients of all ages.
• Convenient Location: With an extensive network of collection points across Karachi and other regions, patients can easily find a Dr. Essa Lab branch close to their home or workplace.
• Commitment to Accurate Diagnosis: As a trusted name in diagnostics since 1987, Dr. Essa Lab maintains rigorous internal and external quality control measures to ensure every test result is highly reliable.